ArticleBiomimetics (Basel, Switzerland)2026
MSGSO: A Multi-Strategy Glider Snake Optimizer for Global Optimization and 3D UAV Path Planning.
Article in Biomimetics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Information in the Glider Snake Optimizer (GSO) propagates through a leader-predecessor chain. This structure is simple, but it can lose diversity when adjacent agents converge to the same region. The proposed Multi-Strategy Glider Snake Optimizer (MSGSO) retains the original GSO update and subsequently applies nonlinear dynamic polynomial mutation (NDM), elite opposition-based learning (EOBL), and quadratic interpolation (QI). MSGSO was evaluated on CEC 2019 and CEC 2022 with 30 matched random seeds and 15,000 objective evaluations for every algorithm-problem pair. The experiments included seven alternative optimizers and all single, pairwise, and three-operator GSO variants. Across the 34 benchmark problems, MSGSO significantly outperformed GSO on 31 and showed no significant loss. It nevertheless ranked third in each external comparison: L-SHADE led CEC 2019 and CEC 2022 at D=10, while CMA-ES led CEC 2022 at D=20. The ablation attributed most of the gain to NDM; NDM-GSO led the GSO variants on CEC 2019, and NDM-QI-GSO led at both CEC 2022 dimensions. In the UAV study, MSGSO returned 29 feasible paths in 30 runs in Scenario 1 and feasible paths in every run in the other two scenarios. It led the feasibility-first ranking in Scenarios 1 and 2 and placed third in Scenario 3. Thus, MSGSO improves its parent algorithm, although the full three-operator sequence is not consistently the best configuration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.